相似文献
1
Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli.
J Clin Microbiol. 2008 Feb;46(2):817-20. doi: 10.1128/JCM.01340-07. Epub 2007 Dec 12.
2
Successful treatment with tigecycline of two patients with complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
J Antimicrob Chemother. 2010 Sep;65(9):2048-9. doi: 10.1093/jac/dkq224. Epub 2010 Jun 16.
3
Are beta-lactams related to higher morbidity and mortality in urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli?
J Hosp Infect. 2008 Feb;68(2):181-3. doi: 10.1016/j.jhin.2007.11.014. Epub 2008 Jan 14.
4
Therapeutic options for bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli.
Clin Infect Dis. 2010 Jul 1;51(1):119-20; author reply 120-1. doi: 10.1086/653446.
5
[Evaluation of antibiotic treatments for urinary tract infections in the elderly, especially regarding the effect on extended spectrum β-lactamase producing (ESBL-) Escherichia coli: A comparison between meropenem and alternatives].
Nihon Ronen Igakkai Zasshi. 2015;52(2):153-61. doi: 10.3143/geriatrics.52.153.
6
Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.
BMJ Open. 2015 Mar 31;5(3):e007363. doi: 10.1136/bmjopen-2014-007363.
7
Escherichia coli: development of carbapenem resistance during therapy.
Clin Infect Dis. 2005 May 15;40(10):e84-6. doi: 10.1086/429822. Epub 2005 Apr 13.
8
Increased community-acquired upper urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in children and the efficacy of flomoxef and cefmetazole.
Clin Exp Nephrol. 2019 Nov;23(11):1306-1314. doi: 10.1007/s10157-019-01775-w. Epub 2019 Aug 19.
9
Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
J Antimicrob Chemother. 2009 Oct;64(4):824-8. doi: 10.1093/jac/dkp254. Epub 2009 Jul 29.
10
Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate.
J Antimicrob Chemother. 2006 Jun;57(6):1262-3. doi: 10.1093/jac/dkl102. Epub 2006 Mar 24.
引用本文的文献
1
Recurrent Urosepsis Following Stent Removal for Ureteral Stones: A Case Report.
Case Rep Urol. 2025 Apr 23;2025:5547651. doi: 10.1155/criu/5547651. eCollection 2025.
2
Pharmacokinetic and pharmacodynamic evaluation of the atypical tetracyclines chelocardin and amidochelocardin in murine infection models.
Microbiol Spectr. 2024 Jan 11;12(1):e0128923. doi: 10.1128/spectrum.01289-23. Epub 2023 Dec 4.
3
Role of tigecycline in the treatment of urinary tract infections: a systematic review of published case reports.
Infez Med. 2022 Dec 1;30(4):516-524. doi: 10.53854/liim-3004-5. eCollection 2022.
4
Role of Tigecycline for the Treatment of Urinary Tract Infections.
J Pharm Technol. 2014 Jun;30(3):87-92. doi: 10.1177/8755122513519332. Epub 2014 Jan 7.
5
Efficacy and safety of tigecycline for complicated urinary tract infection: a systematic review.
Transl Androl Urol. 2021 Jan;10(1):292-299. doi: 10.21037/tau-20-959.
6
Tigecycline treatment of urinary tract infection and prostatitis: case report and literature review.
Can J Hosp Pharm. 2012 May;65(3):209-15. doi: 10.4212/cjhp.v65i3.1144.
7
Ertapenem-induced reduction in valproate levels: case report and review of the literature.
Can J Hosp Pharm. 2010 Jul;63(4):315-22. doi: 10.4212/cjhp.v63i4.936.
8
Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine.
Antimicrob Agents Chemother. 2011 Dec;55(12):5893-9. doi: 10.1128/AAC.00387-11. Epub 2011 Oct 3.
9
Current and novel antibiotics against resistant Gram-positive bacteria.
Infect Drug Resist. 2008;1:27-44. doi: 10.2147/idr.s3545. Epub 2008 Sep 9.
10
Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.
Antimicrob Agents Chemother. 2011 Mar;55(3):1162-72. doi: 10.1128/AAC.01402-10. Epub 2010 Dec 20.
本文引用的文献
1
Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role.
Int J Antimicrob Agents. 2007 Jul;30(1):11-8. doi: 10.1016/j.ijantimicag.2007.02.002. Epub 2007 Apr 17.
2
The pharmacokinetic and pharmacodynamic profile of tigecycline.
Clin Infect Dis. 2005 Sep 1;41 Suppl 5:S333-40. doi: 10.1086/431674.
3
Evaluation by monte carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers.
Antimicrob Agents Chemother. 2005 May;49(5):1881-9. doi: 10.1128/AAC.49.5.1881-1889.2005.
4
Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock.
Intensive Care Med. 2004 Apr;30(4):536-55. doi: 10.1007/s00134-004-2210-z. Epub 2004 Mar 3.
5
Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration.
Chemotherapy. 2003 Dec;49(6):280-6. doi: 10.1159/000074527.
6
Correlation between candiduria and departmental antibiotic use.
J Hosp Infect. 2003 Mar;53(3):183-6. doi: 10.1053/jhin.2002.1354.
7
Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration.
Antimicrob Agents Chemother. 1998 Sep;42(9):2421-4. doi: 10.1128/AAC.42.9.2421.
Zotero 插件